Efficacy and tolerability of vindesine in the treatment of small-cell lung cancer. A phase II study.

Eighteen patients suffering from small-cell lung cancer, all with measurable lesions, were treated with vindesine (3 mg/m2 i.v. on days 1 and 8 of a 21-day cycle). Partial responses (PR) were seen in six patients (three of whom had been previously heavily treated). Most patients tolerated the drug extremely well, an important consideration when expected cure rates are very poor.